FORT COLLINS, CO and ROCKVILLE, MD – February 8, 2012 – Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies. Under this agreement, ABL will be responsible for the production and characterization of a master virus seed stock, a reservoir of virus produced under strict cGMP conditions, which will be used to support Inviragen’s development of a vaccine against plague. In addition, ABL will develop purified vaccine material to be used in future toxicology studies.

“We believe that our expertise in cGMP manufacturing of viral products will provide Inviragen with the support they need in their development of a plague vaccine candidate,” said Dr. Thomas VanCott, CEO of ABL. “Theirs is an innovative and insightful vaccine approach, and we look forward to working closely with Inviragen to help advance this vaccine program into the clinic and establish the basis for a long-term collaborative relationship.”

About Inviragen Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen’s vaccine to protect against dengue fever is in Phase 2 clinical testing. Vaccines to protect against Chikungunya, hand, foot and mouth disease, and Japanese encephalitis which affect millions of individuals in Asia, are in clinical research and development. Vaccines in preclinical research stages include a low-cost human papilloma virus vaccine, vaccines to protect against new forms of influenza and a combination plague/smallpox vaccine for biodefense. Inviragen has offices in Colorado, Wisconsin and Singapore. See www.inviragen.com for more details.

About ABL

Advanced BioScience Laboratories, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing the development of therapeutics, vaccines and other biologic products. ABL has extensive experience working with diverse organizations, including government and academic entities and commercial bio/pharmaceutical companies. Notable services include basic research, product design, process and assay development, preclinical in vivo models (including immunomonitoring), and Phase I/II cGMP biologics manufacturing. Since 2001 ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.

Inviragen Contact:
Joe Brewoo
Scientist
jbrewoo@inviragen.com

ABL Contact:
Andrew Arrage
Vice President, Business Development
301-816-5209